Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

“…In addition, the results clearly show that vaccination affects neither HIV viremia nor the CD4 ϩ T-cell count, as previously reported (24).…”

“…With regard to these serological requirements, no significant differences between vaccine groups were observed, either among infected or among uninfected individuals. The immunogenicity results are only partially in agreement with those of a previous study conducted with HIV-1-seropositive subjects receiving highly active antiretroviral therapy (24), which showed better immune stimulation with Fluad than with Agrippal vaccination. In order to take into account the generally high baseline seroprotection rates among the study population, comparative immunogenicity analysis was also conducted using Beyer's method, correcting for the presence of preexisting antibodies.…”

“…The availability of influenza virus vaccines with adjuvants, such as those containing the oil-in-water emulsion MF59, has recently opened new, interesting perspectives for the prevention of the disease, not only in elderly subjects but also in adults belonging to well-recognized risk categories (3,4,17,24). Several studies of the elderly have demonstrated the higher immunogenicity of influenza virus vaccines with MF59 adjuvant than of split or subunit vaccines with no adjuvant (13,19,31,38,44).…”

Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine

“…The characteristic depletion of CD4 T cells in untreated HIV infection has been associated with reduced Ab responses to TIV (18,30). We therefore examined in HIV-positive subjects any relationship between baseline CD4 T cell counts (Fig.…”

Correlates of vaccine protection from influenza and its complications

“…Furthermore, an MF59-adjuvanted vaccine was studied in open, randomized trials in adult HIV patients and compared with unadjuvanted TIV. [104][105][106] The adjuvanted vaccine was safe and immunogenic, inducing better immune responses in this risk group. However, these data must be cautiously interpreted because efficacy studies designed to assess prevention of infection or define correlates of protection have not yet been performed with these vaccines in these risk groups.…”